| |

Interview with Patrick Moher, CEO of Microdose

Similar Posts

  • The Spotlight Round Up Video, March 17th

    As we continue to strive to be the leading source for news and unique perspective within the emerging sector of medicinal psychedelics, we are excited to debut the Spotlight Roundup! This video series, produced in collaboration with Elk’s Pride Pictures, provides a concise and informative roundup related to some of the most important news developments happening within this rapidly expanding industry. From the latest IPO’s, to new clinical trials, the Spotlight Roundup covers everything you need to know!

  • Bad NEWS for NUMI, FieldTrip and J&J || Esketamine to Treat DEPRESSION Study Results And More

    Hey Psychedelic Investors! There’s been so much news this week that we decided to split “This Week In Psychedelic Stocks” in 2 parts. Part Deux: ” BIG esketamine study results, new 5MEO-DMT tests and Updates on the decriminalization efforts in California and Texas.

    In this episode, there’s lots of news for the psychedelic industry writ large. We’ll start up with three different studies that were released in the first week of April.

    1. We’ll cover some interesting and maybe disappoint results coming from a study designed to determine whether esketamine can treat depression and their implications on some companies such as Numinus Wellness (NUMI), Field Trip Health ( FTRP) and Johnsons & Johnson (JNJ)
    2. Study looking at the creativity benefits of taking psilocybin
    3. Compass Pathways (CMPS) has amazing new price targets
    4. First ever clinical trial testing the safety profile of a compound called 5MEO – DMT
    5. A couple of updates on decriminalization efforts

    Timestapms:

    0:00 – Intro
    1:33 – Likelihood of Adverse events from Nasal Esketamine : Implications for Numinus, JNJ and Fieldtrip Health
    6:07 – Psilocybin’s effects on creativity in a new placebo-controlled neuroimaging and it’s effects on MindMed (MMED/MMEDF), Compass Pathways (CMPS), Mydecine (MYCO) , Numinus ( NUMI)
    11:25 – Researchers to team up to produce the first ever 5-meo-DMT Psychedelic Training Program
    12:28 – California bill To Legalize Possession of Psychedelics Clears Second Senate Committee
    14:26 – Rick Perry supports the Texas Capital to study psychedelic drugs from PTSD in veterans.

    I hope you guys found some value in this! As our thumbnail titles states: The SHROOM BOOM is REAL! Psychedelics are taking the world by storm and psychedelic inspired companies are releasing news every single day. We’ll try to cover most of them but if there’s a company you want us to cover more in debt, please let us know in the comments and we’ll try to satisfy your demands.

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

    Follow us on social media! 🙌
    Instagram: @psychedelicinvestor
    Facebook: @thepsychedelicinvestor

    If you want to collaborate shoot us an email at: thepsychedelicinvestor@gmail.com

    Music: www.bensound.com
    https://benzinga.grsm.io/jameshallifa
    ​…

    https://benzinga.grsm.io/thepsychedel

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #PsychedelicStocks ​#Numi #Mindmed

  • MindMed Stock Price Targets [How HIGH can $MMED / $MMEDF Go?]🚀

    Today we are going to discuss my 5 year price targets for MindMed, MMEDF on the American OTC market, MMED on the Canadian Neo market and MMQ on the European Frankfurt Stock exchange.

    Piggy backing off of a decades worth of positive research showing that substances like LSD, Ibogaine, psilocybin and MDMA can treat mental health illnesses better than current methods by an order of magnitude, MindMed is in my opinion by far the most advanced psychedelic medicines company that retail investors can buy on the public markets which is why MindMedicine is one of my top psychedelic stocks in 2021.

    In this video, we’re going to look at 4 different 5 year price targets for MindMed, and assign them a level of probability. The four cases will be:
    1. The 5 year bear case for MindMed’s stock
    2. The Neutral case for MindMed LT
    3. The bull case price target for MindMed
    4. The Super Bull case

    Timestamps:
    0:00​ – Intro
    2:54 – The Bear Case for MindMed
    5:37 – The Neutral Case/ MindMed’s Stagnation
    7:49 – The Bull Case for MMED/MMEDF Stock
    10:18 – The Super Bull Case for MindMed
    13:08 – Note of Caution Plus Answer to Meor’s Nasdaq question

    Just as a brief note, in this video we are going to be using MMEDF, and all figures will be in American dollars

    And because this is all going to be speculation, the entirety of the episode will take place in, The Speculation Zone

    I hope you guys found some value in this and I’ll keep you posted for more changes!

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌
    Instagram: @psychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    #MindMed​​​ ​#MindmedStock​​​ #MMEDNews